Evaluation and Management of Vaginal Discharge in Postmenopausal Women
A postmenopausal woman with one week of vaginal discharge requires immediate office-based diagnostic testing—specifically vaginal pH measurement, whiff test, and wet-mount microscopy—to differentiate between the three most common infectious causes (bacterial vaginosis, candidiasis, and trichomoniasis) and to exclude atrophic vaginitis or malignancy. 1, 2
Initial Diagnostic Approach
Perform three point-of-care tests during the pelvic examination:
Measure vaginal pH using narrow-range pH paper applied directly to vaginal secretions 3, 1
Perform the whiff test by adding 10% KOH to vaginal discharge 3, 1
Examine wet-mount microscopy using both saline and KOH preparations 3, 1
Do not rely on discharge appearance or symptoms alone—laboratory confirmation is mandatory because symptoms and physical findings have poor diagnostic accuracy 1, 4
Specific Clinical Presentations
Vulvovaginal Candidiasis
- Thick, white "cottage-cheese" discharge with severe vulvar pruritus and erythema 1
- Normal vaginal pH (3.8–4.5) with no odor 1
- Yeast or pseudohyphae visible on KOH preparation 1
Bacterial Vaginosis
- Homogeneous thin white-gray discharge coating vaginal walls 3, 1
- Fishy odor enhanced after KOH application 3, 1
- Elevated pH > 4.5 with clue cells on wet mount 3, 1, 2
Trichomoniasis
- Copious yellow-green frothy discharge with fishy or foul odor 1
- Elevated pH > 4.5 with motile trichomonads on wet mount 1, 2
- Critical caveat: Wet-mount microscopy misses 20–60% of trichomoniasis cases 1
When Microscopy is Negative or Equivocal
Send nucleic acid amplification testing (NAAT) for Trichomonas vaginalis, Neisseria gonorrhoeae, and Chlamydia trachomatis when 1:
- Clinical suspicion remains high despite negative wet mount
- Mucopurulent cervical discharge is present
- STI risk factors exist
Wet-mount microscopy has only 40–80% sensitivity for trichomoniasis, making NAAT essential when clinical suspicion persists 1
Treatment Recommendations
Vulvovaginal Candidiasis
First-line: Topical azole agents (80–90% symptomatic relief) 1
- Clotrimazole 1% cream 5g intravaginally for 7–14 days, OR
- Clotrimazole 100mg vaginal tablet daily for 7 days, OR
- Miconazole 2% cream 5g intravaginally for 7 days
Alternative: Fluconazole 150mg orally as single dose 1, 2
Bacterial Vaginosis
First-line: Metronidazole 500mg orally twice daily for 7 days (≈95% cure rate) 1, 2
Alternatives: Metronidazole 0.75% intravaginal gel or clindamycin cream 1
Trichomoniasis
First-line: Metronidazole 2g orally as single dose (88–95% cure) 1, 2
Alternative: Metronidazole 500mg orally twice daily for 7 days 1
Mandatory partner treatment: Sexual partners must be treated simultaneously to prevent reinfection 1, 2
Special Considerations for Postmenopausal Women
Atrophic vaginitis must be excluded in postmenopausal women presenting with vaginal discharge 3. If microscopy shows only epithelial cells and lactobacilli with pH < 4.5 and no odor, this represents physiologic discharge requiring no treatment 1
For women on tamoxifen or other SERMs: Provide annual gynecologic assessment and advise reporting any vaginal spotting or bleeding, as these drugs increase endometrial cancer risk 3
Follow-Up and Referral Criteria
- Reassess within 1 week if symptoms persist after completing therapy 1
Refer to gynecology for: 1
- Persistent symptoms despite appropriate therapy
- Suspicion of chronic inflammatory dermatoses (lichen planus, lichen sclerosus)
- Presence of ulceration or scarring
- Recurrent episodes (≥4 episodes/year) requiring long-term suppressive therapy
For recurrent candidiasis (≥4 episodes/year), initiate 10–14 days of topical or oral azole therapy followed by fluconazole 150mg once weekly for 6 months 1